Investors of Mydecine Innovations Group (NEO: MYCO)(OTCMKTS: MYCOF) received a pleasant surprise Tuesday morning, drawing coverage from a firm that is making itself known in the psychedelics industry. Roth Capital Partners (RCP), a privately-owned investment banking firm dedicated to the smallcap public market—bestowed an eye-opening price target that instantly captured the market’s attention.
RCP initiated coverage on Mydecine with a “Buy” Rating and C$3.00 price target, which is a 916.94% premium to MYCO’s closing price of $0.295/share before market open on June 22. Not only did RCP recommend that investors buy Mydecine, it is projecting the company to rise 9-fold within the next twelve months. Quite the conviction call for a company in deep penny-stock territory in a sector which has been sputtering.
Read More
Roth Initiates Coverage On Mydecine Innovations With A 9x Price Target
Magic mushrooms by daanibaer is licensed under CC BY 2.0